Purple MHC I dominant epitope peptide of ebola virus nucleoprotein, and coding gene and application thereof
The pan-MHC I dominant epitope peptide of Ebola virus nuclear protein was screened through bioinformatics, which solved the problem of low immune response of Ebola virus nuclear protein antigen peptide in the prior art, and achieved high affinity and immunity The original and conservative epitope design improves the immune efficiency and safety of the vaccine.
Patent Information
- Application Number
- CN202411229001.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art lacks the EBOV NP antigen peptide that can effectively activate the body's immune response, and the immune response is low, making it difficult to design a wide and long-lasting immune protection vaccine.
The pan-MHC I dominant epitope peptide of Ebola virus nuclear protein was predicted and screened through bioinformatics methods, and combined with a variety of computational tools to predict its binding affinity, immunogenicity and conservatism with MHC class I molecules, and designed a high level of design A 9-peptide epitope with affinity, high immunogenicity and interspecies conservative intraspecies, used for vaccine design and immune response activation.
These dominant epitope peptides can effectively stimulate the body's cellular immune response, overcome the impact of individual differences and ethnic regional distribution characteristics on the effect of vaccines, provide a wider and safe antiviral application prospect, and improve the immune efficiency and safety of vaccines.
Smart Images

Figure CN119080879A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pathogenic microorganism immunology, and specifically relates to a pan-MHC I dominant epitope peptide of an Ebola virus nucleoprotein, a coding gene thereof and an application thereof. Background Art
[0002] Ebola virus (EBOV) is a virulent pathogen of the Filoviridae family. Infection with the virus can cause a severe acute disease, namely Ebola hemorrhagic fever, which manifests as multiple organ failure and shock, with a mortality rate of up to 80%. The pathogen Ebola virus (EBOV) includes five subtypes: Zaire, Bundibuyo, Sudan, Reston and Tyson. Among them, the Zaire Ebola virus was discovered in 1976 and is the most deadly.
[0003] EBOV is a single-stranded negative-sense RNA virus belonging to the Filoviridae family. Its genome has seven genes, encoding nucleoprotein (NP), viral protein (VP) 35, VP40, VP24, VP30, polymerase (L gene) and glycoprotein (GP). NP plays a key role in Ebola virus replication and is an essential component of the virus life cycle. Studies have shown that certain segments in EBOV NP are CD8 + The EBOV-NP vaccine can rapidly induce NP-specific CD8 T cells to produce interferon-γ (IFN-γ). + In addition, compared with other EBOV proteins, NP is more conservative and is considered to be a more suitable target for CTL vaccines.
[0004] Virus-specific CD8 + The activation of effector T cells requires antigen presenting cells (APCs) to present viral antigens through major histocompatibility complex (MHC) class I molecules. Only peptides with high affinity and tight binding to MHC class I molecules can be expressed on the surface of APC cells and presented to CD8 + T cell recognition and immunogenic peptides can trigger subsequent immune responses. Therefore, immunoreactivity and immunogenicity are crucial to elucidating antiviral immunity. At the same time, evolutionarily conserved epitopes are often essential for viral survival. Therefore, vaccination containing conserved epitopes plays an important role in providing broad and lasting immune protection.
[0005] Recently, epitope-based vaccines have become an important direction for vaccine design and antiviral immunotherapy. Rationally designed epitope vaccines can not only reduce adverse reactions to improve safety, but also benefit a wider population, ultimately improving the immune efficiency of the vaccine. Currently, there are few known EBOV NP antigen peptides that can effectively activate the body's immune response, and the immune response reactivity is low. Therefore, it is urgent to screen and identify new EBOV NP dominant epitope peptides with high immune response reactivity. Summary of the invention
[0006] In view of the above technical problems, one of the purposes of the present invention is to provide a pan-MHC I dominant epitope peptide of Ebola virus nucleoprotein, wherein the amino acid sequence of the dominant epitope peptide is one of SEQ ID NOs. 1 to 4. The pan-MHC I dominant epitope peptide has high affinity, high immunogenicity and conservation between species and within species, can effectively stimulate the body's cellular immune response, and can help improve the design of epitope vaccines against Ebola virus in the future.
[0007] The second object of the present invention is to provide a gene encoding the dominant epitope peptide.
[0008] The third object of the present invention is to provide the use of the dominant epitope peptide in the preparation of a drug for inducing or enhancing an Ebola virus-specific immune response.
[0009] A fourth object of the present invention is to provide the use of the dominant epitope peptide in the preparation of a product for preventing and / or treating diseases caused by Ebola virus infection.
[0010] The fifth object of the present invention is to provide the use of the gene in the preparation of a product for inducing or enhancing an EBOV-specific immune response.
[0011] The sixth object of the present invention is to provide the use of the gene in the preparation of products for preventing and / or treating diseases caused by Ebola virus infection.
[0012] Furthermore, in the above application, the product is an epitope vaccine.
[0013] The seventh object of the present invention is to provide an Ebola virus epitope vaccine, the immunogen of which comes from the dominant epitope peptide.
[0014] Furthermore, the vaccine also includes a pharmaceutically acceptable carrier.
[0015] Furthermore, the vaccine may or may not contain an adjuvant.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] The present invention predicts potential epitopes of EBOV Makona NP (gene number: MG572234.1), including the binding affinity, immunogenicity and inter-species and intra-species conservation of these epitopes with pan-MHC class I molecules, which will help understand the immunobiology of EBOV NP and help improve the design of epitope vaccines against Ebola virus in the future. The dominant epitope peptide of the present invention can be regarded as a viral subunit that can effectively stimulate the body's cellular immune response, that is, a highly conserved region required for the function of the virion. The epitope can be used to design a polypeptide vaccine. The purpose of this strategy is to inoculate the "minimal structure composed of clear antigens" to stimulate an effective specific cellular immune response, and in theory overcome the influence of individual differences and ethnic regional distribution characteristics on the effect of vaccine application. It has incomparable advantages over traditional vaccines, and is safe and convenient to use, and has broad application prospects in the antiviral process. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Interaction of EBOV NP 9 peptide with pan-MHC-I molecules.
[0019] Figure 2 Affinity heat map of EBOV NP 9 peptide and pan-MHC-I molecules.
[0020] Figure 3 It is a docking model of species-selective epitopes and corresponding MHC-I alleles.
[0021] Figure 4 The results of 4 9-peptide dominant epitopes were verified by ELISPOT experiment. DETAILED DESCRIPTION
[0022] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0023] Example 1
[0024] 1: Amino acid sequence search:
[0025] The glycoprotein sequence of Ebola virus Makona NP (NP, sequence number: ATY51132.1) was obtained from the NCBI GenBank database and used as input for various bioinformatics tools for epitope prediction, conservation analysis, and molecular docking.
[0026] 2: Epitope prediction:
[0027] A total of 33 MHC class I genotypes were involved, including mouse MHC genotypes of H2-Db, H2-Dd, H2-Kb, H2-Kd, H2-Kk and H2-Ld subtypes, and participated in the subsequent epitope prediction. The human major leukocyte antigen (HLA)-I class subtype selection cumulatively covered genotypes of more than 97% of the population, including HLA-A1 (-A*0101, HLA-A*2601, -A*3001, -A*3002), HLA-A2 (HLA-A*0201, -A*0203, -A*0206, -A*6802), HLA-A3 (HLA- A*0301, -A*1101, -A*3001, -A*3101, -A*3301, -A*6801), HLA-A24 (HLA-A*2301, -A*2402, -A*3201), HLA-B7 (HLA-B*0702, -B* 3501, -B*5101, -B*5301), HLA-B8 (HLA-B*0801), HLA-B15 (HLA-B*1501), HLA-B44 (HLA-B*4001, -B*4402, -B*4403) and HLA-B58 (H LA-B*5701, -B*5801). Web-based tools such as the IEDB method (http: / / tools.iedb.org / mhci / ), the SMMPMBEC method from the Immune Epitope Database (http: / / tools.immuneepitope.org / mhci / ), the NetMHCpan4.1 method (http: / / www.cbs.dtu.dk / services / NetMHCpan / ), the SYFPEITH method (http: / / www.syfpeithi.de / bin / MHCServer.dll / EpitopePrediction.htm) and the Rankpep method (http: / / imed.med.ucm.es / Tools / rankpep.html) were used for prediction. The predicted epitopes with the top 2% affinity were selected for subsequent screening.
[0028] As mentioned above, bioinformatics analysis was performed using a variety of computational tools to predict potential MHC class I epitopes with different binding affinities for EBOV nucleoprotein. Epitopes that appeared three or more times in the five prediction software were considered dominant epitopes; if one of the five prediction software did not include the subtype, epitopes that appeared two or more times in the remaining prediction software were considered dominant epitopes. There are 731 9-peptides in the full length of EBOV nucleoprotein. Tables 1 and 2 list the number of dominant epitopes generated by each prediction tool. After recalculating and excluding repeated 9-peptides, we obtained 73 dominant epitopes in the H-2 subtype and 236 dominant epitopes in the HLA class I subtype. In the H-2 subtype, H2-Dd has the largest number of dominant epitopes, which is 31. In the HLA class I subtype, HLA-A3 has the largest number of dominant epitopes, which is 72.
[0029] Table 1 Number of HLA-I dominant epitopes of EBOV NP
[0030]
[0031]
[0032] Table 2 Number of dominant mouse MHC-I epitopes of EBOV NP
[0033]
[0034]
[0035] 3: Computer analysis:
[0036] 3.1 Pan-MHC 9-peptide clustering analysis:
[0037] The polymorphism of MHC-I molecules and the diversity of epitope peptide amino acid sequences form the interaction between them. In order to visualize the relationship between them, TBtools was used to perform bidirectional hierarchical clustering on the affinity index of the aforementioned 33 pan-MHC-I genotypes and 731 9 peptides of EBOV NP. After the affinity ranking data were processed with the base 2 logarithm and Z-Score, the bidirectional hierarchical clustering of Euclidean distance was performed using the Complete method. The higher the score, the stronger the affinity of the peptide to the MHC-I molecule, and a heat map was drawn to visualize it.
[0038] Figure 1The affinity patterns between different MHC I genotypes and the full-length 9 peptides of EBOV NP were shown. The 33 MHC class I molecules were divided into 3 groups, including HLA I subtype group, cross-reaction group (HLA-dominant), and cross-reaction group (H2-dominant). In the HLA I subtype group, although HLA-A3001 belongs to the HLA-A1 superfamily, its score is more similar to that of HLA-A3 (-A0301, -A1101, -A3101, -A3301, -A6801), suggesting that the HLA-A3001 genotype exhibits HLA-A3-like characteristics in presenting EBOV NP antigens. For the cross-reaction group (H2-dominant), the H2-Ld score is similar to that of HLA-B7 (-B0702) and HLA-B8 (-B0801). In the cross-reactive cluster (HLA major), H2-Kd scored similarly to HLA-B24 (-A2301, -A2402); H2-Kk scored similarly to HLA-B44 (-B4001, -B4402, -B4403).
[0039] 3.2 Binding affinity analysis:
[0040] Based on the affinity scores between EBOV NP 9 peptides and different MHC-I molecules, a heat map was drawn to show the regional affinity ( Figure 2 ). EBOV NP derived 731 single-residue promoted 9-peptides on the distribution of 740 amino acids. The data are from the Rank value of NetMHCPan4.1. The heat map is listed as MHC-I genotype and the behavior is different epitopes. The smaller the %Rank and the darker the color, the higher the binding affinity of the peptide to the corresponding MHC-I genotype.
[0041] From the figure, it can be concluded that the epitope binding strength is regionally distributed. The ranges of No.13-No.21, No.148-No.155, No.189-No.206, No.228-No.243, No.386-No.413, No.520-No.536, No.640-No.695, No.712-No.731 have good affinity. No.480-No.519, No.537-No.548, No.562-No.573, No.581-No.595 have poor binding ability.
[0042] 3.3 Immunogenicity Analysis:
[0043] High-affinity peptides may not be able to fully induce an immune response. In addition to immunoreactivity, antigens should also be immunogenic. Therefore, we used IEDB (http: / / tools.iedb.org / immunogenicity / ) and the R language-based PAAQD algorithm to analyze the immunogenicity of the screened EBOV NP high-affinity 9-peptide epitopes. IEDB used a score > 0 as a positive standard, and PAAQD used a score > 0.5 as a positive standard. The peptide was considered to be immunogenic, otherwise it was not immunogenic. Finally, the 9 peptides that were considered to be immunogenic by both tools were selected as the final immunogenic peptides.
[0044] The results are shown in Table 3. 58 of the 236 HLA-I subtype dominant epitopes were considered to be immunogenic; 14 of the 73 H2 subtype dominant epitopes were immunogenic. In addition, there were 12 9 peptides that were cross-human and mouse, that is, they were both high-affinity and highly immunogenic HLA-I epitopes and high-affinity and highly immunogenic H2 epitopes. These 12 epitopes were defined as interspecies selective epitopes.
[0045] Table 3 Immunogenicity of EBOV NP MHC-I restricted dominant epitopes
[0046]
[0047]
[0048] 3.4 Conservatism analysis
[0049] In order to determine the degree of evolutionary conservation of the dominant antigenic epitopes in the Ebola virus species sequence, the BLASTp tool was used to perform conservation analysis on the predicted high-affinity 9 peptides. Among them, the intra-species conservation evaluation standard was Zaire disease virus (taxid: 186538) except Makona Zaire virus (taxid: 1891187); the inter-species conservation evaluation standard was Ebola virus (taxid: 186536) except Zaire disease virus (taxid: 186538). At the same time, the conserved peptide sequences between EBOV and humans (taxid: 9606) or mice (taxid: 10088) were excluded. In the analysis results, if the E value <10 -5 ,, is considered conservative. Based on this conservative state, dominant epitopes can be divided into four categories: interspecies-intraspecies-, interspecies-intraspecies+, interspecies+intraspecies-, and interspecies+intraspecies+.
[0050] The conservation analysis of the above-mentioned 12 species selective epitopes showed that none of the 12 epitopes were conserved among species, while the epitopes LEEEYPPWL, SQGPFDAVL, SFEEMYRHI, and FEEMYRHIL were conserved within species and could provide a certain degree of cross-immune protection.
[0051] Example 2: Application of dominant epitope peptides of Ebola virus nucleoprotein
[0052] The invention lays a foundation for the research of novel genetic engineering vaccines of EBOV by predicting the dominant MHC I epitope peptides on EBOV NP and performing various computer analyses.
[0053] 1: Peptide-MHC Molecular Docking
[0054] HPEPDOCK is a new type of web server that can simulate molecular docking by inputting 9-peptide sequences and MHC class I molecule RDB format files to obtain the docking model. The required MHC class I molecule 3D structure data can be obtained using the RCSB PDB database (https: / / www.rcsb.org / ) {HLA-A1 [HLA-A*0206(3OXR)], HLA-B7 [HLA-B*0702(5EO1), HLA-B*3501(1A9E), HLA-B*5101(1E28), HLA-B*5301(1A1N)], HLA-B8 [HLA-B*0 801(4QRP)], HLA-B15 [HLA-B*1501(1XR9), HLA-A*0101(4NQV)], HLA-B44 [HLA-B*4402(3KPL)], H2-Ld(6L9M), H2-Kb(6JQ3), H2-Db(1JUF)}. The docking of each 9-peptide with an MHC class I molecule will generate 100 simulated docking models, and the first 10 simulated docking results are generally considered to be the most credible computer prediction results.
[0055] The results are as follows Figure 3 As shown in the figure, the top ten docking modes and docking scores of the 12 dominant epitopes were obtained by docking with human and mouse MHC-I molecules, and the lower the score, the better the peptide-MHC docking performance. The results showed that the docking scores of epitopes LEEEYPPWL, GEYAPFARL, IVRQRVIPV, LEHGLFPQL, TEANAGQFL, VAQARFSGL, SFEEMYRHI, with HLA-I molecules were lower than those with H-2, that is, the docking performance of these 9 epitopes in HLA-I subtype was better than that of mouse H-2 subtype. On the contrary, epitopes SQGPFDAVL, APFARLLNL, SAPDDLVLF, FEEMYRHIL, and SGRNIKRTL may have better docking performance with mouse H-2 subtype.
[0056] The above 12 selective epitopes are all high-affinity and highly immunogenic, and the types and numbers of genotypes with high affinity to each epitope are different. Among the 12 epitopes, 8 have 3 or more high-affinity genotypes with HLA-I, suggesting that they have a wider range of population application effects. Among these 8 epitopes, APFARLLNL and SAPDDLVLF not only have the largest number of high-affinity genotypes with HLA-I, but also have 3 high-affinity genotypes with H2, which is the largest number in mice, suggesting that they have better pan-MHC characteristics, so they were selected for subsequent wet experiment verification. Among the remaining 6 epitopes, FEEMYRHIL is located in the strong binding region of the EBOV NP antigen epitope. In addition to the aforementioned characteristics, it can also represent a strong binding region epitope, so it was selected for subsequent wet experiment verification. Among the remaining 5 epitopes, the molecular docking results showed that TEANAGQFL had better docking results with the most HLA-I genotypes than H-2. If it is verified to be effective, it can indicate that it has better potential immune response in people with multiple HLA-I genotypes, which is of great significance, so it was selected for subsequent wet experiment verification. Accordingly, the epitopes APFARLLNL (SEQ ID NO.1), SAPDDLVLF (SEQ ID NO.2), FEEMYRHIL (SEQ ID NO.3), and TEANAGQFL (SEQ ID NO.4) were selected for subsequent experimental verification.
[0057] 2: Peptide synthesis:
[0058] The corresponding peptides were synthesized according to the selected peptide sequence. All 9 peptides used in the experiment were completed by Shanghai Chupeptide Biotechnology Co., Ltd. with a purity of 95% and 9 mg / peptide. After centrifugation of the synthesized 2 mg peptide powder, 20 μL of dimethyl sulfoxide (DMSO) was added to dissolve it, and then 480 μL of sterile ddH2O was added to mix well and frozen in a -20°C refrigerator for use.
[0059] 3: Enzyme-linked immunosorbent spot (ELISpot) test verification:
[0060] Construction of EBOV NP nucleic acid vaccine: According to the Zaireebolavirus / 2014 / Makona NP sequence published in GenBank (MG572234.1), codon optimization was performed, and a Bgl II restriction site was introduced upstream of the sequence, a Sal I restriction site was introduced downstream, a Kzaok sequence was added, and a 3×Flag tag was attached to the C-terminus of GP / NP to facilitate subsequent identification of vaccine antigen expression. Qingke Bio was commissioned to perform standard gene synthesis according to the designed sequence, inserted into the Kan-resistant pVAX1 vector, and then transformed into the Escherichia coli TOP10 strain for delivery. The plasmid was used as an EBOV NP nucleic acid vaccine to immunize mice and then experimentally verify the selective epitope.
[0061] Use sterile complete medium to dilute the synthetic mouse high-affinity and highly immunogenic 9-peptide to a final concentration of 20 μg / mL for ELISpot assay. First dilute the IFN-γ specific capture antibody with sterile PBS solution to a final concentration of 5 μg / mL, then add 100 mL per well to a 96-well plate and incubate overnight at 4°C. Then seal the 96-well plate with RPMI 1640 medium containing 10% fetal bovine serum at room temperature for 2 hours. The spleen cell suspension of the collected mice (three weeks after the second immunization with EBOV NP nucleic acid vaccine) was lysed of red blood cells, and the spleen cells were resuspended in RPMI 1640 medium containing 10% fetal bovine serum at a rate of 1×10 per well. 6 The number of spleen cells was added to a 96-well plate, and then an equal volume of diluted 9 peptides was added. The negative control was RPMI1640 medium containing only 10% fetal bovine serum and 1% double antibody, and the positive control was 10g / mL concanavalin A (Con A). Incubate in a 37°C, 5% CO2 incubator for 24 hours. After incubation, wash the plate with double distilled water and PBST. After washing, add 100ul of biotinylated anti-IFN-γ detection antibody with a final concentration of 2pg / mL to the well and incubate at room temperature for 2 hours. After washing with PBST, add streptavidin-horseradish peroxidase (streptavidin-HRP) and incubate at room temperature for 1 hour. After washing with PBST, add AEC substrate for color development and wash with water to terminate the reaction. After the 96-well plate is air-dried, use the CTL-immunoSpot plate reader to scan and count the spots in the 96-well plate. All results are shown as every 10 6 The bar graph was drawn using GraphPad Prism 9.0.0.
[0062] Four immunogenic H-2-restricted 9-peptide dominant epitope peptides were artificially synthesized for ELISpot test verification. The peptides were used to stimulate the spleen cells of mice immunized with pVAX-NP EBOV plasmid to observe the secretion of IFN-γ. Figure 4 Displayed as every 10 6 The figure shows that the splenocytes of BALB / c mice can secrete IFN-γ after being stimulated by the four 9-peptide peptides.
[0063] The above research found that the dominant MHC I epitope peptide on EBOV NP has high affinity, immunogenicity and conservation between species and within species. At the same time, molecular docking simulated a possible docking model, which can also play a good role in dealing with Ebola virus mutations.
[0064] In recent years, although EBOV vaccines have been developed at home and abroad, from the application situation, such vaccines still have many shortcomings, including poor stimulation of the body's cellular immune response and certain safety risks. The EBOV NP dominant MHC class I epitopes screened by the method of the present invention, if used in stimulating the body's cellular immune response, will have the following advantages:
[0065] 1. After viral infection, antigen presenting cells (APC) present antigenic peptides through MHC class I molecules to activate CD8 + T cells. For MHC class I molecules, both ends of the antigen binding groove are blocked by conserved tyrosine residues, resulting in the size of the binding peptide being usually limited to 8-10 amino acid residues. Therefore, we selected a 9-amino acid peptide as the predicted epitope. At the same time, the cellular immune response mediated by CTL plays an important role in antiviral infection. After CTL recognizes virus-infected cells (target cells), it releases perforin and granzyme memory through the FasL-Fas pathway, causing the target cells to lyse and die, thereby effectively clearing virus-infected cells in the body. The level and activity of a virus-specific CTL in the body are positively correlated with the clearance effect of the virus.
[0066] 2. Neutralizing antibodies can specifically bind to viruses to prevent them from infecting host cells, but for already infected host cells, CD8 + T cells exert cytotoxic effects to clear intracellular infected viruses.
[0067] 3. Peptide prediction methods are used to predict the binding affinity of each 9-peptide to a specific MHC class I molecule. Currently, there are many different principles for predicting peptide affinity algorithms, so we use multiple prediction methods to predict peptides with stronger binding affinity, making the results more credible and less biased. At the same time, we performed immunogenicity analysis on all predicted 9-peptides to eliminate non-immunogenic epitopes with high affinity.
[0068] 4. Previous studies were more focused on the HLA-A*02 subtype. In the present invention, we predicted 33 MHC class I molecule genotypes, including 27 human genotypes and 6 mouse genotypes. It can be said that our selective epitopes have pan-MHC-I reactivity, overcoming the differences in MHC-I molecules caused by population and regional distribution. Immune effects can be produced among different races in different regions, which helps to obtain a broader and more effective herd immunity.
[0069] 5. After analyzing the conservation of the 9-peptide dominant epitopes among and within the species of Ebola virus, the dominant epitopes can be simply classified. Compared with other epitopes, the dominant epitopes that are conserved among and within species are more suitable for vaccine development and immune research. The dominant mouse epitopes with high affinity and strong immunogenicity were simulated and docked with the corresponding mouse MHC class I and human HLA class I molecules, and all produced immune docking effects. Among them, 4 antigen epitopes were verified by ELISpot test and showed that they could induce immune response of mouse spleen cells.
[0070] In the present invention, the peptide affinity prediction, immunogenicity analysis and conservation analysis of EBOV NP were performed by using bioinformatics methods, and the docking simulation of peptides and MHC class I molecules was also performed, which provided new ideas for subsequent Ebola virus-related immunological research and contributed to the future design of epitope-based anti-EBOV epitope vaccines. At the same time, the methods of high-affinity peptide prediction and subsequent related analysis can also be used for basic immune research of other pathogens and prevention and control of infectious diseases. In addition, there are also literatures proving that epitope prediction can be used for the treatment and intervention of cancer.
[0071] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0072] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A pan-MHC I dominant epitope peptide of Ebola virus nucleoprotein, characterized in that: The amino acid sequence of the dominant epitope peptide is one of those shown in SEQ ID NOs. 1 to 4.
2. A gene encoding the dominant epitope peptide according to claim 1.
3. Use of the dominant epitope peptide according to claim 1 in the preparation of a drug for inducing or enhancing an Ebola virus-specific immune response.
4. Use of the dominant epitope peptide according to claim 1 in the preparation of a product for preventing and / or treating diseases caused by Ebola virus infection.
5. Use of the gene according to claim 2 in the preparation of a product for inducing or enhancing an EBOV-specific immune response.
6. Use of the gene according to claim 2 in the preparation of a product for preventing and / or treating diseases caused by Ebola virus infection.
7. The use according to claim 4 or claim 5 or claim 6, characterized in that: The product is an epitope vaccine.
8. An Ebola virus epitope vaccine, characterized in that: The immunogen is derived from the dominant epitope peptide described in claim 1.
9. The Ebola virus epitope vaccine according to claim 8, characterized in that The vaccine also includes a pharmaceutically acceptable carrier.
10. The Ebola virus epitope vaccine according to claim 9, characterized in that: The vaccine may or may not contain an adjuvant.
